Oral Oncology
Volume 45, Issue 12 , Pages e216-e221 , December 2009

Relationship between molecular markers and treatment response in a retrospective cohort of Indian patients with primary carcinoma of the larynx

  • R. Sahoo

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • V. Chittibabu

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • G. Patil

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • S. Rao

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • S. Thakur

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • G. Dhondalay

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • A.J. Kulkarni

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • A. Banerjee

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • B.S. Ajaikumar

      Affiliations

    • HCG Foundation, No. 8, P. Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • A. Korlimarla

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • A. Nargund

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • R.N. Niti

      Affiliations

    • HCG Foundation, No. 8, P. Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • K.S. Gopinath

      Affiliations

    • HCG Foundation, No. 8, P. Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • Shilpa Prabhudesai

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • ,
  • R.M. Raghavendra

      Affiliations

    • Triesta Sciences (India) Pv Ltd., No. 8, Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • HCG Foundation, No. 8, P. Kalinga Rao Rd., Sampangiramanagar, Bangalore 560027, India
    • Corresponding Author InformationCorresponding author. Address: Research Head, Investigator Initiated Trials, Triesta Sciences Pvt. Ltd., HCG Towers, No. 8, P. Kalinga Rao Road, Sampangiramanagar, Bangalore 560027, India. Tel.: +91 80 40206122/9916488864; fax: +91 80 22485962.

Received 12 June 2009 ,Revised 16 July 2009 ,Accepted 16 July 2009.

References 

  1. National Cancer Registry Programme-Biennial Report (1988-89) of the National Cancer Registry Programme. New Delhi: Indian Council of Medical Research 1992; 3-42.
  2. Mehrotra R, Singh M, Kumar D, Pandey AN, Gupta RK, Sinha US. Age specific incidence rate and pathological spectrum of oral cancer in Allahabad. Indian J Med Sci. 2003;57:400–404
  3. Mehrotra R, Singh M, Gupta RK, Singh M, Kapoor AK. Trends of prevalence and pathological spectrum of head and neck cancers in North India. Indian J Cancer. 2005;42(2):89–93
  4. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693–3704
  5. Juvekar AS, Amonkar AJ, D’cruz AK, Saikaia T, Pradhan S. Chemosensitivity of advanced Larynx Carcinoma cells in vitro and significance of multidrug resistance markers in these tumors. Cancer Biother Radiopharm. 1998;13(2):81–87
  6. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20:435–439
  7. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev. 1999;99:2451–2466
  8. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–194
  9. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685–90.
  10. el-Deiry WS. P21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol. 1998;227:121–137
  11. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331
  12. Moll UM, Schramm LM. P53—an acrobat in tumorigenesis. Crit Rev Oral Biol Med. 1998;9:23–37
  13. Wynford-Thomas D. P53: guardian of cellular senescence. J Pathol. 1996;180:118–121
  14. Bradford CR, Zhu S, Wolf GT, Poore J, Fisher SG, Beals T, et al. Over expression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg. 1995;113(4):408–412
  15. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003;25(8):654–661
  16. Weinstein JN, Myers TG, O’Connor PM, Friend SH, Fornace AJ, Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 1997;275(5298):343–349
  17. Kovach JS, Hartmann A, Blaszyk H, et al. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci. 1996;93:1093–1096
  18. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood. 1997;89(2):601–609
  19. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84(9):3148–3157
  20. Bradford CR, Zhu S, Poore J, Fisher SG, Beals TF, Thoraval D, et al. p53 Mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg. 1997;123(6):605–609
  21. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. P53 and treatment of bladder cancer. Nature. 1997;385:123–125
  22. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996;56:892–898
  23. Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995;55(8):1649–1654
  24. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci. 1999;55:64–75
  25. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. P53 mutation and loco regional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1580–1586
  26. Mineta H, Borg A, Dictor M, Akervall J, Wennerberg J. P53 mutation, but not p53 over expression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer. 1998;78:1084–1090
  27. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene. 1998;16:1671–1679
  28. Ahomadegbe JC, Barrois M, Fogel S, LeBihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of p53 alterations (mutation, deletion, over expression) in head and neck primary tumors and metastases: absence of correlation with clinical outcome—frequent protein over expression in normal epithelium and in early noninvasive lesions. Oncogene. 1995;10:1217–1227
  29. vanOijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res. 2000;6:2138–2145
  30. Bradford CR, Zhu S, Poore J, Fisher SG, Beals TF, Thoraval D, et al. P53 mutation as a prognostic marker in advanced laryngeal carcinoma: Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg. 1997;123:605–609
  31. Bradford CR, Wolf GT, Carey TE, Zhu S, Poore J, Beals TF, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999;121:534–538
  32. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope. 2002;112(4):638–644
  33. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 1995;9(7):882–895
  34. Kumar B, Cordell KG, D’Silva N, Prince ME, Adams ME, Fisher SG, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008;134(4):363–369
  35. Bharaj BS, Angelopoulou K, Diamandis EP. Rapid sequencing of the p53 gene with a new automated DNA sequencer. Clin Chem. 1998;44(7):1397–1403
  36. McGee S. Simplifying likelihood ratios. J Gen Int Med. 2002;17(8):646–649
  37. Yamazaki Y, Chiba I, Hirai A, Sugiura C, Notani K, Kashiwazaki H, et al. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol. 2003;39:163–169
  38. Georgiou A, Gomatos IP, Ferekidis E, Syrigos K, Bistola V, Giotakis J, et al. Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. Eur J Surg Oncol. 2001;27:574–580
  39. Hoft S, Maune S, Muhle C, Brenner W, Czech N, Kampen W, et al. Sentinel lymph-node biopsy in head and neck cancer. Br J Cancer. 2004;91:124–128
  40. Kropveld A, Rozemuller EH, Leppers FGJ, Scheidel KC, de Weger RA, Koole R, et al. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest. 1999;79:347–353
  41. Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfirio B, et al. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int J Cancer. 1999;22;84(6):573–579
  42. Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, et al. P53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol. 2006;45(3):300–305
  43. Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M, et al. Prognostic value of over expression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett. 2003;192(2):227–235
  44. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, et al. Clin Cancer Res. 1995;1(11):1375–1383
  45. Lo Muzio L, Falaschini S, Farina A, Rubini C, Pezzetti F, Campisi G, et al. Bcl-2 as prognostic factor in head and neck squamous cell carcinoma. Oncol Res. 2005;15(5):249–255
  46. Bosch FX, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A, et al. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer. 2004;111(4):530–538
  47. Eriksen JG, Alsner J, Steiniche T, Overgaard J. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radiother Oncol. 2005;76(2):135–142
  48. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10(11):3607–3613
  49. Vikram B. Changing patterns of failure in advanced head and neck cancer. Arch Otolaryngol. 1984;110:564–565
  50. Sutton DN, Brown JS, Rogers SN, Vaughan ED, Woolgar JA. The prognostic implications of the surgical margin in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2003;32:30–34
  51. Leemans CR, Tiwari R, Nauta JJ, Van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer (Phila). 1994;73:187–190
  52. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck. 2002;24(2):198–206
  53. Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res. 2003;63:5649–5655
  54. Martin SJ, Green DR, Cotter TG. Dying with death: dissecting the components of the apoptosis machinery. TIBS (Trends Biochem Sci). 1994;19:26–30
  55. Fnisch SM, Francis H. Disruption of epithelial cell–matrix interactions induces apoptosis. J Cell Biol. 1994;24:619–626
  56. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10(11):3607–3613

PII: S1368-8375(09)00863-X

doi: 10.1016/j.oraloncology.2009.07.013

Oral Oncology
Volume 45, Issue 12 , Pages e216-e221 , December 2009

Article Tools

* Image Usage & Resolution